Clearmind Medicine Completes Phase I/II Dosing for Alcohol Use Disorder Drug, Reports Strong Safety
CMND sits 80% above its 52-week low of $2.1 on light trading volume (0.1× avg).
Summary
Clearmind Medicine has completed dosing for all 24 participants in Part A of its Phase I/II clinical trial for CMND-100, a drug candidate for Alcohol Use Disorder. Interim results from the first three cohorts show a strong safety profile. This marks a significant operational milestone for the clinical-stage biotech, demonstrating progress in its lead program. The positive clinical update provides a counterpoint to the company's recent financial struggles, which include a going concern warning and a series of highly dilutive convertible note financings.
At the time of this announcement, CMND was trading at $3.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $2.10 to $524.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.